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Abstract
Background: Glioblastoma multiforme (GBM) is one of the most highly metastatic cancers. GBM has been associated
with a high level of the mechanistic target of rapamycin complex 2 (mTORC2) activity. We aimed to observe roles
of mTORC2 in GBM cells especially on actin cytoskeleton reorganization, cell migration and invasion, and further
determine new important players involved in the regulation of these cellular processes.
Methods: To further investigate the significance of mTORC2 in GBM, we treated GBM cells with PP242, an
ATP-competitive inhibitor of mTOR, and used RICTOR siRNA to knock down mTORC2 activity. Effects on actin
cytoskeleton, focal adhesion, migration, and invasion of GBM cells were examined. To gain insight into molecular basis
of the mTORC2 effects on cellular cytoskeletal arrangement and motility/invasion, we affinity purified mTORC2
from GBM cells and identified proteins of interest by mass spectrometry. Characterization of the protein of interest
was performed.
Results: In addition to the inhibition of mTORC2 activity, we demonstrated significant alteration of actin distribution as
revealed by the use of phalloidin staining. Furthermore, vinculin staining was altered which suggests changes in focal
adhesion. Inhibition of cell migration and invasion was observed with PP242. Two major proteins that are associated
with this mTORC2 multiprotein complex were found. Mass spectrometry identified one of them as Filamin A (FLNA).
Association of FLNA with RICTOR but not mTOR was demonstrated. Moreover, in vitro, purified mTORC2 can
phosphorylate FLNA likewise its known substrate, AKT. In GBM cells, colocalization of FLNA with RICTOR was observed,
and the overall amounts of FLNA protein as well as phosphorylated FLNA are high. Upon treatments of RICTOR siRNA
or PP242, phosphorylated FLNA levels at the regulatory residue (Ser2152) decreased. This treatment also disrupted
colocalization of Actin filaments and FLNA.
Conclusions: Our results support FLNA as a new downstream effector of mTORC2 controlling GBM cell motility.
This new mTORC2-FLNA signaling pathway plays important roles in motility and invasion of glioblastoma cells.
Keywords: Glioblastoma Multiforme, mTORC2, RICTOR, Filamin A, PP242, Actin cytoskeleton
Background
Glioblastoma multiforme (GBM) is classified as a grade
IV type for malignant gliomas according to the World
Health Organization (WHO) system [1]. It is one of the
most lethal tumors based on survival and recurrence rates
after diagnosis and resistant to both chemo- and radio-
therapeutics. In the past, most cases after initial treat-
ments of GBM such as surgery, radio- and chemotherapy
are occasionally followed by recurring tumors which even-
tually progress to death [2]. The epidermal growth factor
receptor (EGFR) is one of the key contributors that con-
tribute to cancer hallmarks in GBM [3]. EGFR activating
mutations are commonly observed in GBM patients and
the EGFR variant III is the most common type of muta-
tion conferring constitutive signals to many pathways
downstream, mainly PI3K-AKT-mTOR, and MAPK [4–8].
In brain cells, the mechanistic target of rapamycin
complex 2 (mTORC2) has been implicated as one of the
main regulators. Abnormality of mTORC2 signaling path-
way is linked to malignant glioma and has been broadly
studied [9–12]. Several mutations, ablations, deregulated
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signaling pathways including mTORC2 are found to be key
characteristics of malignant glioma [13]. Also, mTORC2 is
believed to maintain neuron morphology and synapse
function which is lacking or deregulated in brain diseases
[14]. Furthermore, hyperactivated mTORC2 with RICTOR
overexpression was evidenced in various types of brain
cancers. Masri et al. [15] showed that elevated mTORC2
activity promotes tumorigenesis, tumor growth and prolif-
eration. Levels of RICTOR protein and mTORC2 activ-
ity can be related to specific stages of cancer invasiveness
[15, 16]. The mTORC2 has been linked to metabolic re-
programming in GBM including glycolytic metabolism,
glutaminolysis, lipogenesis, and nucleotide and ROS me-
tabolism [17]. These activations of several pathways by
mTORC2 are believed to cause resistance to signaling in-
hibitors [18]. Recently, TORC2 in yeast and mTORC2
have also been reported to be new important players in
DNA damage control and genome stability. These pro-
cesses are essential for survival of cancer cells during
stress-mediated DNA damage and also for cancer devel-
opment [19–22].
The mTOR complex 2 (mTORC2) consists of the four
main components which are mTOR, RICTOR, mSIN1
and mLST8 (GβL), and including other closely associ-
ated proteins such as PROTOR1/2, DEPTOR, TTI1 and
TEL2 [23]. mTOR is a serine-threonine protein kinase
that belongs to the phosphoinositide-3-kinase-related
kinase family [24]. The complex is stimulated by growth
factors critical for AKT activation resulting in the phos-
phorylation of AKT residue Ser473 [25]. Activated AKT
further signals downstream to contribute to events such
as cell survival, apoptosis, lipid and glucose metabo-
lisms, and via mTORC1 to promote cell proliferation,
and protein synthesis [26, 27]. On the other hand,
mTORC2 has also been shown to control actin cyto-
skeleton reorganization independent of AKT [28, 29].
One mechanism is by phosphorylating the hydrophobic
motif of SGK1 and several isoforms of PKCs [13, 30, 31]
that are important for transcription regulation, actin
cytoskeleton reorganization [17]. Moreover, mTORC2-
mediating actin polymerization is required for the regu-
lation of both long-term memory formation and long-
term synaptic plasticity in mice [32]. Depletion of mTOR
or RICTOR but not RAPTOR was recently demonstrated
to impair migration, invasion, and stress fiber forma-
tion of highly migratory Tsc2-/- mouse embryonic fibro-
blast cells [33]. However, mechanisms that mTORC2
use to regulate morphology and motility of cells are still
poorly understood.
To gain further insight into the function of mTORC2,
we first examined effects of inhibiting mTORC2 by using
the mTOR kinase inhibitor PP242 [34]. This revealed
alteration of cellular cytoskeleton as well as focal adhe-
sions and inhibition of motility and invasion. Affinity
purification and characterization of mTORC2 from GBM
cells were performed and these led to the finding that Fila-
min A (FLNA) is associated with mTORC2 through its
binding to RICTOR. In fact, FLNA is a substrate of
mTORC2. RICTOR knockdown in GBM cells as well as
PP242 treatment resulted in the inhibition of phosphoryl-
ation of FLNA. The PP242 treatment contributes to the
disruption of colocalization of FLNA and actin. Taken to-
gether, these results suggest that mTORC2 affects FLNA
and results in changes in motility and invasion in GBM.
Results
mTOR inhibitor PP242 inhibits mTORC2 activity and
affects actin cytoskeleton and focal adhesion
A GBM cell line U87vIII was used. This cell line is be-
lieved to be a good model for GBM that expresses EGF
receptor variant III (EGFR vIII) [5, 35]. Treatment of
these cells with PP242, an ATP-competitive inhibitor of
mTOR kinase, causes significant decrease of mTORC2
and mTORC1 activities, as detected by the phosphoryl-
ation of AKT at Ser473 and S6 at Ser235/236, respect-
ively (Fig. 1a). On the other hand, mTORC2 is relatively
insensitive to rapamycin. These results were further con-
firmed using starvation condition. Under starvation,
U87vIII cells have constitutively active mTOR pathway
which can be fully enhanced upon nutrients and amino
acids stimulation. The highly phosphorylated downstream
effectors of both mTOR complexes were eliminated after
a 3-h treatment of PP242 (Fig. 1b). The levels of total
AKTand S6 remain the same. PP242 at the concentrations
we used did not inhibit MEK and PAK1 activities, as de-
tected by pERK (Thr202/Tyr204) and pCRKII (Ser41), re-
spectively (Additional file 1: Figure S1A).
PP242 has significant effects on actin cytoskeleton and
focal adhesion. As shown in Fig. 1c, phalloidin staining
of GBM cells revealed the significant alteration of actin
cytoskeleton. While actin cytosekeleton was detected
predominantly on cell periphery without PP242 treat-
ment, intracellular actin became predominant after the
PP242 treatment. Besides, the thickness of membrane-
bound actin filaments became significantly thinner and
disordered. Staining with antibody against vinculin, a
major component of focal adhesion, showed that cells
lost their focal adhesions along the membrane after the
PP242 treatment. We also found that anti-vinculin stain-
ing overlaps with phalloidin staining at the membrane.
These results demonstrate that the inhibition of mTORC2
is associated with significant changes in cellular actin cyto-
skeleton and focal adhesion.
mTOR inhibitor PP242 blocks cell migration and invasion
capability of glioblastoma cells
We found that PP242 has a major effect on motility of
GBM cells. Fig. 2a shows the result of scratch wound
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healing assays to investigate effects of mTORC2 inhib-
ition on cell migration. Prior to the assays, we confirmed
that PP242 did not affect cell density after a 24-h treat-
ment (Additional file 2: Figure S2A). While U87vIII cells
closed the gap caused by scratch wounding after 12 h
(control), PP242 treatment significantly inhibited gap
closing in a dose-dependent manner, suggesting that cell
movement was inhibited (compare the distance that cells
moved at 12 h after the scratch was made). This result is
in contrast to the treatment with rapamycin that exhib-
ited much weaker inhibition of motility. Since rapamycin
predominantly affects mTORC1 under the condition used,
inhibition of mTORC2 appears to contribute to the PP242
effects. Proliferation inhibition is less than 30 % under this
condition (data not shown). Also, treatment with MEK in-
hibitor U0126 did not exhibit significant inhibition of mo-
tility in this scratch wound assay. These results suggest
that mTORC2 plays a major role in GBM cell migration.
The effects of PP242 on the ability of GBM cells to in-
vade through extracellular matrix were examined using
modified transwell Boyden chambers filled with base-
ment membrane extract. U87vIII cells were treated with
PP242, U0126 or rapamycin for 6 h followed by the in-
cubation in no-serum media without drugs. Within this
time frame, proliferation inhibition is minimal. Invaded
cells on the membrane were detected by fixing and
staining with crystal violet (Additional file 2: Figure
S2B). The data shown in Fig. 2b indicate that GBM cells
partially lost their invasive ability to penetrate through
extracellular matrix (ECM) as numbers of cells success-
fully reached the membrane part of the chamber shown
in the chart significantly decreased in PP242-treated
groups. On the other hand, treatment with rapamycin did
not exhibit effects on invasion. Similarly, effects of U0126
were significantly less than that observed with PP242.
These invasion assay results suggest that inhibition of
mTORC2 has significant effect on GBM invasion.
Purification of mTORC2 reveals association of Filamin A
with mTORC2 in glioblastoma cells
The above results imply that mTORC2 plays critical
roles in actin cytoskeleton and motility/invasion of GBM
cells. To gain insight into how mTORC2 influences
these events, we purified and characterized mTORC2
Fig. 1 PP242 inhibits mTORC2 and exerts significant effects on actin cytoskeleton and focal adhesion of U87vIII cells. a PP242 inhibits mTORC1
and mTORC2 activities effectively while rapamycin only inhibits mTORC1 activity. Cells were treated with inhibitors for 24 h and phosphorylation
of AKT and S6 was examined as described in Methods. b U87vIII cells have constitutively active mTORC1 and mTORC2 activities in starved condition.
Stimulation by amino acids and serum fully activate mTOR kinase activity. A 3-h treatment of 2.5 μM PP242 ablates phosphorylation of AKT and S6.
c Actin cytoskeleton and focal adhesion of U87vIII cells treated with PP242 for 24 h were examined using immunofluorescence staining by Phalloidin
(actin) and anti-vinculin (focal adhesion) (Exposure time: actin 254 ms; vinculin 251 ms). Effects of PP242 on these processes were examined by treating
cells with PP242. Effects on actin cytoskeleton rearrangement are clearly visible on the thickness of actin layers on surrounding cell membrane (arrows)
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complexes in U87vIII cells. We stably expressed FLAG-
RICTOR in GBM cell line U87vIII. The mTORC2 com-
plex was prepared from U87vIII cells by carrying out af-
finity purification using FLAG-M2 magnetic beads. The
purified mTORC2 was characterized by SDS polyacryl-
amide gel electrophoresis. In particular, we looked for
mTORC2 associated proteins in a molecular weight range
larger than 135 kDa. As shown in Fig. 3a, in addition to
RICTOR, we detected three bands. Mass spectrometry
was used to identify the proteins in the gel bands. Of the
four bands, we found that the bands number 2 and 4 in
Fig. 3a are mTOR and RICTOR, respectively. Proteins in
bands 1 and 3 were found to be Filamin A (FLNA) and
Myosin-9 (MYH9), respectively (Fig. 3a, right panel).
FLNA is a large cytoplasmic non-muscle actin binding
protein functioning as a signaling scaffold of cytoskeletal
network [36]. MYH9 is known as non-muscle myosin
heavy chain IIA, involved in several processes related to
cellular motility such as cytoskeleton reorganization, focal
contacts formation, and cell migration [37]. It is interest-
ing that both proteins are associated with actin cytoskel-
eton dynamics. Because FLNA is directly involved with
actin cytoskeleton, we focused our attention on FLNA.
The identity of components of mTORC2 pulled down
by anti-FLAG antibody was further confirmed by Western
blot analysis (Fig. 3b). As shown, in addition to mTOR, we
identified SIN1 and FLNA proteins. FLNA is a phosphory-
lated protein modified most notably at Ser2152 [38].
Therefore, we used anti-pFLNA (Ser2152) antibody to see
whether FLNA associated with mTORC2 is phosphory-
lated. As shown in Fig. 3b, we detected phospho-FLNA
band. When mTORC2 is precipitated by the use of anti-
mTOR antibody, we detected bands for RICTOR and
phospho-FLNA, as well as RAPTOR (Fig. 3c). A similar
Fig. 2 mTOR inhibition affects cell migration and invasion. a Wound-healing migration assay of U87vIII cells grown in a single layer. Space between
a scratch is approximately 1 mm wide. Pictures were taken at 12 h after the scratch was made for each sample. Migration of cells treated with PP242,
rapamycin, or U0126 was examined. b Numbers of invaded U87vIII cells through modified Boyden chambers were determined as described in
Methods. Effects of PP242 at 2.5 and 5.0 μM, rapamycin (100 nM) or U0126 (10.0 μM) are shown. Cells were incubated with the inhibitor for 6 h.
Invaded cells attaching to the chamber membrane were stained and the number of cells for each sample group was determined by measuring the
absorbance values of crystal violet-stained cells at 590 nm. (P2.5 = PP242 2.5 μM, P5.0 = PP242 5.0 μM, RAPA = rapamycin 100 nM, U10 = U0126
10.0 μM) Data are the mean ± SD (n = 3). *P < 0.05; **P < 0.005, P-values from two-tailed student t-test (unpaired comparison)
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experiment using anti-RICTOR antibody identified mTOR
and phospho-FLNA. On the other hand, immunoprecipi-
tation using anti-pFLNA (Ser2152) antibody precipitated
mTOR and RICTOR but not RAPTOR. These results sug-
gest that FLNA is specifically associated with mTORC2
and not mTORC1.
RICTOR interacts with Filamin A
Because mTORC2 has multiple proteins associated, we
asked which protein interacts with FLNA. To investigate
this point, we lysed the cells with Triton X-100, a deter-
gent that dissociates mTOR from its partners RAPTOR
or RICTOR [39, 40]. We confirmed that the preparation
of anti-FLAG pulldown obtained in the presence of 1 %
Triton X-100 was devoid of mTOR protein (Fig. 4a).
However, FLNA was still associated with the FLAG-
RICTOR pulldown. In contrast, when CHAPS was used,
RICTOR interacted with mTOR as well as with FLNA.
These results suggest that FLNA is associated with RIC-
TOR but not with mTOR.
Further support for the interaction between FLNA and
RICTOR was obtained by the demonstration that these
proteins colocalize in U87vIII cells. Fig. 4b shows im-
munofluorescence staining of two different GBM cells
using anti-FLNA or anti-RICTOR antibody. DAPI stain-
ing was carried out to stain the nucleus. We found that
most of FLNA and RICTOR colocalize with each other,
especially the ones residing along the cell membrane
(see yellow staining in the merged figure in Fig. 4b). In
addition, mTOR also colocalizes with FLNA as shown in
Additional file 3: Figure S3. These results show that RIC-
TOR, mTOR and FLNA are physically located close by.
Filamin A is phosphorylated by mTORC2 in vitro
In the previous experiments, we showed that FLNA as-
sociated with mTORC2 is phosphorylated (Fig. 3b and
c). This led us to examine whether FLNA serves as a
Fig. 3 Purification, identification, and characterization of mTORC2 and its binding partners. a Silver-stained high molecular weight mTORC2
components purified from U87vIII cells stably expressing FLAG-RICTOR are shown. Four large proteins (numbered as 1-4) were analyzed by mass
spectrometry after being run on 7 % SDS-PAGE gel, excised, then digested by Trypsin. Mass spectrometry results are summarized in the table on
the right. Filamin A (FLNA) and Myosin-9 (MYH9) represent unknown bands 1 and 3, respectively. †Mascot protein score; a protein with score
value >21 with >2 unique peptides is considered significant (P <0.05). b Immunoblots of purified proteins from U87vIII cells showing main components
of mTORC2 (mTOR, RICTOR, SIN1) including phosphorylated and total FLNA. c Immunoprecipitation of U87vIII cell lysate by protein G Dynabeads
coupled with antibodies against main components of mTOR complex 1 and 2. Phosphorylated FLNA was co-immunoprecipitated with anti-mTOR and
anti-RICTOR coated beads while these two components of mTORC2 were pulled down with anti-pFLNA coated beads. RAPTOR, an mTORC1-specific
component, can be co-immunoprecipitated with anti-mTOR coated beads but not with anti-pFLNA beads
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substrate for mTORC2 kinase activity. mTORC2 was puri-
fied from U87vIII cells and phosphorylation of FLNA at
its regulatory residue Ser2152 was examined using FLNA
C-terminal fragment as a substrate. As shown in Fig. 5a,
dose-dependent phosphorylation of FLNA was detected.
In this experiment, phosphorylation of AKT residue
Ser473 was used as a positive control. Similar results were
obtained with mTORC2 purified from HEK293T cells
(Additional file 4: Figure S4C). Additionally, we confirmed
that phosphorylation of FLNA substrate was catalyzed
specifically by mTOR kinase activity, not by other kinases
potentially contaminating the mTORC2 preparation. This
was performed by carrying out an in vitro kinase assay of
which two samples included PP242 at 1.25 μM and
5.0 μM. The results shown in Fig. 5b demonstrate that
PP242 promotes a dose-dependent, significant inhibition
of FLNA phosphorylation compared to those without the
inhibitor. In contrast, the level of phosphorylated FLNA is
not reduced in the sample containing PAK1 inhibitor.
Filamin A phosphorylation is regulated by mTORC2 in
glioblastoma cells
We noticed that the levels of total and phosphorylated
FLNA are significantly higher in GBM cells compared
with HEK293T cells. This is shown in Fig. 6a. The basal
level of FLNA in U87vIII is relatively higher than in
HEK293T cells, while the amount of mTOR kinase is
similar in both cell lines. More strikingly, we observed a
dramatically higher level of phospho-FLNA (Ser2152) in
U87vIII compared with HEK293T cells. The total amount
of AKT is slightly higher in U87vIII cells and the amount
of phospho-AKT is significantly higher in these cells.
Thus, GBM cells exhibit dramatically increased levels of
phosphorylated FLNA and AKT. Previous studies showed
that the level of FLNA in more metastatic cancer cells is
higher than in lower grade cancer cells of the same type
[41, 42], suggesting the significance of FLNA in cancer
progression and metastasis.
To investigate whether mTORC2 is responsible for
FLNA phosphorylation at residue Ser2152 in vivo, we
attempted to eliminate mTORC2 activity by depleting
mTORC2 component, RICTOR, using siRNA. As shown
in Fig. 6b, the level of RICTOR was significantly de-
creased by RICTOR siRNA but not by scrambled siRNA
(Sc). The treatment with RICTOR siRNA resulted in the
decrease of phosphorylated FLNA (Ser2152) in U87vIII
cell lines while the total amount of FLNA was un-
changed. The RICTOR siRNA treatment also decreased
Fig. 4 RICTOR binds FLNA. a FLAG-RICTOR is pulled down after lysing U87vIII cells with CHAPS or Triton X-100 as a detergent in lysis buffer. An
immunoblot shows that RICTOR is associated with mTOR and FLNA in samples from CHAPS-treated extracts but only with FLNA in Triton X-100-treated
extracts b Immunofluoresence labeling of two individual U87vIII cells grown in normal condition. Majority of FLNA and RICTOR colocalize along cell
membrane and cytoplasm. Anti-FLNA antibody and Anti-RICTOR antibody were used to stain FLNA and RICTOR, respectively (Exposure time: FLNA
334 ms; RICTOR 540 ms; DAPI 41 ms). However, only RICTOR is found in nuclei of the cells. Overall results indicate that FLNA is an mTORC2 associated
protein which is a binding partner of RICTOR
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the level of phosphorylated AKT (Ser473). These results
suggest that mTORC2 is a primary player in FLNA
phosphorylation.
Moreover, inhibition of mTORC2 due to the depletion
of RICTOR caused effects on actin filaments (Fig. 6c).
Disordered and thin membrane-bound filaments were
observed in a siRNA-treated group. FLNA proteins were
also relocated in response to RICTOR knockdown. The
shift of FLNA localization from the predominant mem-
brane area to perinuclear/nuclei area is clear when com-
paring scrambled siRNA-treated group and RICTOR
siRNA-treated group.
PP242 inhibits Filamin A phosphorylation and causes
dissociation of Filamin A from actin cytoskeleton
We treated U87vIII cells with varying concentrations of
an mTOR ATP-competitive inhibitor PP242 that can in-
hibit mTORC2 kinase activity, and then the level of
phospho-FLNA (Ser2152) was examined. As can be seen
in Fig. 7a, the levels of phosphorylated FLNA decreased
significantly in a dose-dependent manner. The amount of
total FLNA, on the other hand, was unchanged by the
treatment. PP242 also inhibited phosphorylation of FLNA
(Ser2152) in HEK293T cells (Additional file 4: Figure S4D).
We found that FLNA colocalizes with actin cytoskel-
eton in GBM cells. As shown in Fig. 7b, the staining pat-
tern of cells with anti-FLNA antibody looked similar to
that observed with phalloidin staining (see the appear-
ance of yellow fluorescence in the merged panel). After
U87vIII cells were treated with 2.5 μM PP242 for 24 h,
FLNA proteins and actin filaments were dissociated and
were no longer colocalized, as revealed by the disappear-
ance of yellow fluorescence in the merged panel. FLNA
localization changes from plasma membrane to perinuclear
area and into the nuclei. Stronger effects can be observed
in cells treated with a higher concentration of PP242.
Discussion
GBM has been depicted as one of the most invasive
types of cancer [2, 43]. In this paper, we have shown that
PP242, an ATP competitive inhibitor of mTOR, inhibits
mTORC2 and exerts dramatic effects on actin cytoskel-
eton and focal adhesion in GBM cells. Moreover, PP242
causes inhibition of migration, as examined by scratch
wound assay, while rapamycin or MEK inhibitor has
only limited effect. In addition, PP242 inhibits invasion of
GBM cells. By characterizing mTORC2 purified from
GBM, we have found that Filamin A (FLNA) is an
mTORC2 associated protein. This is confirmed by co-IP
experiments. We have also shown that FLNA is phosphor-
ylated by mTORC2 in vitro and in vivo. Inhibition of
mTORC2 by RICTOR siRNA or PP242 treatment results
in the inhibition of FLNA phosphorylation and dissoci-
ation of FLNA from actin cytoskeleton. Taken together,
Fig. 5 Purified mTORC2 phosphorylates FLNA at Ser2152 in vitro. a In vitro kinase assay of mTORC2 purified from U87vIII cells with FLNA and AKT
as substrates. Level of phosphorylated FLNA (Ser2152) and phosphorylated AKT (Ser473) were increased in the presence of mTORC2 and ATP.
Negative control groups contain either no purified complex or no ATP. Activity of mTORC2 is maximal when Mn2+ is used instead of Mg2+. b In vitro
kinase assay of mTORC2 purified from U87vIII cells with FLNA as a substrate. Two concentrations of PP242 (+ = 1.25 μM; ++ = 5.0 μM) and one
concentration of IPA3 (+ = 40 μM) were added into three samples to inhibit the kinase activity of mTORC2. Levels of pFLNA and pAKT when
treated with PP242 are decreased compared to ones without PP242
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our results suggest that mTORC2/FLNA axis is critical for
actin cytoskeleton, motility and invasion of GBM cells.
FLNA is ubiquitously expressed in non-muscle cells
[38], and this 280 kDa actin binding protein serves as an
essential organizer of cell structure and function by
assisting in cell shape maintenance and organization of
cytoskeletal networking, providing cell plasticity, and pro-
tecting cells from shearing stresses [44]. Because FLNA
crosslinks cortical actin filaments to cell membrane, cell
protrusions such as filopodia, lamellipodia, and pseudopo-
dia can be initiated [36, 45]. FLNA also provides connec-
tion between various cytoskeletal proteins in cytoplasm to
integrin localizing on the plasma membrane. In this man-
ner, FLNA can anchor F-actin to various transmembrane
proteins [46]. Getting released from FLNA, the integrin is
activated and functional in propelling the cells [38, 47].
Fig. 6 mTORC2 regulates FLNA phosphorylation at Ser2152. a An immunoblot showing high amounts of phosphorylated FLNA (pFLNA) and
phosphorylated AKT (pAKT), a known mTORC2 substrate, in U87vIII cell lysate. In contrast, the amount of mTOR is similar in both U87vIII and
HEK293T cells. b Level of FLNA phosphorylation (Ser2152) in U87vIII cells treated with two different concentrations of RICTOR siRNA decreases
correlating to mTORC2 inhibition as detected by pAKT at Ser473. (Sc: scrambled siRNA, + = 4 μL, ++ = 8 μL siRNA). c Immunofluorescence staining
of actin filaments, FLNA and RICTOR (Exposure time: RICTOR 318 ms; actin 580 ms; FLNA 123 ms). Results obtained from RICTOR knockdown
experiment (48-h incubation with RICTOR siRNA) as described in Methods were used to observe effects of mTORC2 loss on arrangement of actin
cytoskeleton and FLNA localization
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Thus, the mTORC2/FLNA axis plays important roles in
cellular functions relating actin cytoskeleton, motility and
invasion. In addition, both FLNA and mTORC2 could
affect small GTPases known to control actin cytoskeleton
(Rho), and chemotaxis and accumulation of F-actin (Rac/
cdc42) [48].
By dissociating mTORC2 complex, we have shown
that FLNA binds RICTOR but not mTOR. Since RIC-
TOR is a specific component of mTORC2 (while RAP-
TOR is a specificity protein for mTORC1), this result
explains specific effects of mTORC2 on actin cytoskel-
eton, motility and invasion. We further showed that
RICTOR and FLNA are colocalized in GBM cells. Once
associated with mTORC2, FLNA is phosphorylated by
mTOR. This was shown first by demonstrating that
mTORC2 purified from U87vIII cells could phosphoryl-
ate FLNA and this phosphorylation is inhibited by
PP242. Second, knockdown of mTORC2 by applying
RICTOR siRNA resulted in the inhibition of FLNA
phosphorylation in U87vIII cells. These results suggest
that FLNA is a new substrate of mTORC2. The specific
site of phosphorylation, Ser2152, is located on FLNA’s
repeat 20 that is involved with the migration and inva-
sion properties of cancers [47]. In addition, this site is
associated with the binding of the protein to C-terminal
region of β-integrin [38], suggesting that multiple inter-
actions occur at this specific location of FLNA, and
pointing to the importance of Ser2152 in maintaining in-
tegrity of the protein and initiation of several cellular
activities.
According to our findings, it appears that mTORC2-
mediated phosphorylation of FLNA is a primary event in
GBM migration and invasion, even though FLNA can be
phosphorylated by multiple protein kinases including
Fig. 7 PP242 inhibits FLNA phosphorylation and causes dissociation of FLNA from actin cytoskeleton. a Levels of pFLNA (Ser2152) in U87vIII cells
treated with different concentrations (0.31-5.0 μM) of PP242 were examined by carrying out Western analysis using anti-phospho-FLNA antibody.
Average relative signal intensity of pFLNA adjusted by total FLNA amount of each condition is shown. Error bars indicate ± SD (n = 3). b Effects of
PP242 on actin cytoskeleton and FLNA localization were examined by treating U87vIII cells with PP242 (2.5 μM or 5.0 μM) for 24 h before fixation.
Immunofluorescence staining of actin filaments and FLNA was carried out as described in Methods (Exposure time: FLNA130 ms; actin 250 ms;
DAPI 55 ms). Colocalization of Actin and FLNA is interrupted in samples treated with PP242. The results resemble effects of the treatment with
siRNA against RICTOR
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cyclic AMP (cAMP)-dependent protein kinase (PKA),
p90 ribosomal kinase (RSK), PAK1, cyclin D1/Cdk4 and
PKCα [49–52]. Our results shown in Additional file 1:
Figure S1A demonstrate that MEK inhibitor (U0126),
inhibiting upstream regulators of RSK, and PAK1 inhibi-
tor (IPA3) did not significantly affect phosphorylation of
FLNA compared to PP242. While FLNA is associated
with mTORC2, we did not observe PKCα association
with isolated complexes (Additional file 1: Figure S1B).
Taken together, it appears that mTORC2 plays critical
roles in the phosphorylation event of FLNA.
We found that FLNA is overexpressed and highly
phosphorylated at Ser2152 in GBM cells. This presum-
ably reflects high level of mTORC2 activation in these
cells perhaps due to overexpression of RICTOR. We
have shown that phosphorylation of FLNA by mTORC2
is important for cytoskeletal effects. Inhibition of FLNA
phosphorylation by ATP-competitive mTOR inhibitor
(PP242) leads to impaired FLNA-actin-plasma mem-
brane linkages and disorganization of actin cytoskeleton
in addition to the disruption of FLNA-actin colocaliza-
tion. FLNA appeared to move inward to the perinuclear
area after being inactivated by the inhibitor. Similarly,
inhibiting mTORC2 by knocking down RICTOR results
in the inhibition of FLNA phosphorylation and this
causes dramatic change in actin cytoskeleton and FLNA
localization. From the recent study, knockdown of FLNA
impairs migration of neuronal cells, disrupts actin cyto-
skeleton and defects filopodia formation [53]. Therefore,
both FLNA knockdown and inhibition of phosphoryl-
ation by PP242 affect actin cytoskeleton.
Our studies reinforce the idea that FLNA is a critical
player in GBM. FLNA was firstly shown to be associated
with P311 protein, and colocalize on the leading edges
of glioma cells [54]. Highly expressed P311 is involved
with invasive glioma migration by acting downstream
of β1-integrin. Disruption of β1-integrin affects P311-
mediated Rac1, Cdc42 activation, and finally inhibits
cell migration [54]. Recent findings established that
metastasis of GBM is related to the activity of calpain-2
enzyme, accounting for proteolysis of its substrates;
Talin and FLNA through the maintenance of extracel-
lular matrix metalloproteinases 2 (MMP2) [55, 56].
FLNA may be significant in migration, invasion and
metastasis of other cancers also. From previous studies,
FLNA appears to be overexpressed in several types of
cancers, such as prostate cancer, breast cancer, lung
cancer, colon cancer, melanoma, and neuroblastoma [47].
Involvement of FLNA in cancer metastasis was sug-
gested in multiple other studies [57–59]. In addition,
Zhang L et al. reported that overexpression of FLNA in
Tsc1null neurons promoted abnormal dendritic pattern-
ing which is a common shared feature of neurodevelop-
mental diseases [60].
Another protein that we found associated with purified
mTORC2 is Myosin-9 (MYH9 or NMHC-IIA). MYH9 is
a member of class II actin motors with ATPase activity
that promote formation of lamellipodia, filopodia, and
membrane ruffles [37, 61]. This machinery is critical for
various developmental processes of the cells such as em-
bryogenesis, organogenesis, and immune synapse forma-
tion [62]. Many kinases in several signaling pathways have
been shown to regulate MYH9 [63]. Abnormalities of
MYH9 and its associated proteins cause multiple types of
diseases including cancers [62]. Also, MYH9 was reported
to play important roles in breast cancer motility and gli-
oma invasion [64, 65]. Further work is needed to investi-
gate whether MYH9 is a component or substrate of
mTORC2 and what role it plays in mTORC2 function.
In summary, our results highlight the importance of
mTORC2-FLNA lineage in glioblastoma multiforme,
and suggest that FLNA is associated with mTORC2 as a
new downstream target. mTORC2 activates FLNA by
phosphorylating its biological regulatory site Ser2152
which elicits actin cytoskeletal changes and further affects
cell motility and invasiveness. Future work should uncover
signaling events involving the mTORC2-FLNA axis in
GBM.
Conclusions
Taken together, our results provide the evidence to dem-
onstrate that FLNA is a new downstream effector of
mTORC2. Inhibition of mTORC2 resulted in the de-
creased level of phosphorylated FLNA, and led to de-
fects in the organization of actin networks. Therefore,
we propose that the new mTORC2-FLNA signaling
pathway could be the key regulator in motility and inva-
sion of glioblastoma cells.
Methods
Antibodies and other reagents
Anti-FLAG M2 magnetic beads, 3X FLAG peptide,
Phalloidin-FITC, anti-Vinculin (VCL), and PP242 were
obtained from Sigma-Aldrich. Anti-AU1 agarose beads
were from BETHYL Lab. AU1 peptide (DTYRYI) was
from COVANCE. Recombinant C-terminal fragment
(amino acids 1730–2639) of Human FLNA purified from
E. coli was obtained from Creative Biomart. Full-length
inactive recombinant AKT1/PKB was from EMD Millipore.
Anti-mTOR, Anti-phospho-AKT(Ser473), Anti-AKT, Anti-
phospho-FLNA(Ser2152), Anti-phospho-S6(Ser235/236),
Anti-S6, Anti-phospho-ERK (Thr202/Tyr204), and Anti-
ERK were obtained from Cell Signaling. Anti-FLNA was
obtained from EMD Millipore. Anti-RICTOR and anti-
SIN1 were obtained from BETHYL Lab. Anti-phospho-
CRKII and Anti-CRKII (Ser41) were obtained from Santa
Cruz Biotechnology.
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Cell culture
U87 overexpressing EGFR vIII (U87vIII) and HEK293T
cells were maintained in DMEM containing 10 % (vol/
vol) FBS, 1 % (vol/vol) penicillin/streptomycin at 37 °C
with 5 % (vol/vol) CO2. Stable U87vIII and HEK293T
cells expressing FLAG-RICTOR protein were established
using lentivirus containing pRK-5-myc-RICTOR plasmid
(Addgene plasmid # 1860) [29] generated by the UCLA
Vector Core Facility.
Drug treatment
U87vIII cells were cultured in DMEM containing 10 %
(vol/vol) FBS, 1 % (vol/vol) penicillin/streptomycin at 37 °C
with 5 % (vol/vol) CO2 until they reached 80 % confluency.
Cells were serum starved in serum-free media for 24 h
prior to a 24-h treatment of different concentrations of
rapamycin or PP242 in regular culturing media. We have
shown that PP242 at the highest concentration (5 μM) did
not inhibit ERK or PAK1 activity, confirming specific ef-
fects on mTORC2 prior to its usages in other experiments
(Additional file 1: Figure S1A).
Western blotting
Cultured cells were lysed with a lysis buffer containing
0.2 % Triton X-100 and protease inhibitor cocktail
(EDTA-free PIC; Roche). The amount of total protein
concentration in cleared lysate was determined by Bio-
Rad protein assay. Equal protein extracts from various
samples were separated by electrophoresis on SDS-
PAGE gel, and then transferred to a nitrocellulose mem-
brane (GE Healthcare). The membrane was blocked in
Tris-buffered saline containing 0.05 % Tween20 and 5 %
bovine serum albumin, then probed with primary anti-
bodies followed by secondary antibodies (Horseradish
peroxidase (HRP)-conjugated). The blot was incubated
in Pierce ECL Western Blotting Substrate solution
(Thermo Scientific). Protein bands from peroxidase ac-
tivities to chemiluminescent substrates were developed
and detected on films.
Immunofluorescence
U87vIII cells were fixed with 4 % Paraformaldehyde,
lysed with 0.2 % Triton X-100 buffer, blocked with 1 %
BSA, then incubated in primary antibodies (anti-FLNA,
anti-VCL, anti-RICTOR, anti-mTOR, FITC-phalloidin)
overnight at 4 °C or 3 h at room temperature. Anti-
mouse (Texas Red conjugate), and anti-rabbit (Alexa
Flour 594 conjugate and Alexa Flour 488 conjugate)
secondary antibodies from Life Technology were used.
Nuclei of cells were stained by DAPI. FLNA, Actin fila-
ments, RICTOR, and VCL, were observed using a
fluorescence microscope.
Wound healing migration assay
U87vIII cells were plated onto several 35 mm collagen-
coated culture dishes (Sigma- Aldrich) until the surface
of each dish was covered by a monolayer of cells. A sin-
gle scratch per plate was made using a small pipette tip
creating a 1 mm wide linear gap. Phase contrast images
of all sample groups were taken at hour 0 before drug
administration. Cells were treated with PP242 2.5 μM,
rapamycin 100 nM, U0126 5 μM for 12 h, then images
were acquired again.
Transwell invasion assay
U87vIII cells were serum starved for 24 h prior to the
experiment. One hundred thousand cells were treated
with DMSO or drugs (rapamycin, PP242, or U0126) at
different concentrations for 6 h in serum-free DMEM.
Then, the media was changed to new 200 μl of serum-
free media without drugs. Cells in drug-free media were
transferred to an upper chamber of a 6.5 mm transwell
insert with a 8.0 μm pore polycarbonate membrane
(modified Boyden chamber) coated with 2-3 mg/ml
basement matrix extract (BME) (Cultrex; Trevigen). In
each lower chamber we added 500 μl of DMEM with
10 % FBS. The 24-well plates were incubated at 37 °C
for 24 h. After that, DMEM and BME in the upper com-
partment were removed, and cells on the bottom of the
membrane were washed in PBS. The membranes were
then fixed in chilled methanol for 10 min following by
crystal violet staining for 25 min. Cells were destained
by acetic acid, and transferred to a 96-well plate. Ab-
sorbance representing relative cell numbers of each sam-
ple group was detected at 590 nm. Cell migration of
each group was determined with the use of modified
Boyden chamber without BME coating. Absorbance value
from migrated cells of the control group (with DMSO)
represented one hundred thousand cells. Absolute num-
bers of invaded cells under different conditions were cal-
culated by comparing the ratio of absorbance values from
invaded cells to migrated cells.
Statistical analysis
Statistical analysis of cell invasion assay was performed
using absolute numbers of invaded cells from sample
groups. Statistically significant differences between two
data sets were assessed with the two-tailed, unpaired
Student’s t-test, with P-values of P < 0.05 sufficient to re-
ject null hypothesis.
Purification of mTORC2
U87vIII and HEK293T cells were infected with the
FLAG-RICTOR lentivirus and cells stably expressing
FLAG-RICTOR were obtained by puromycin selection.
The drug-selected cell lines were cultured and grown,
collected after washing with PBS, and stored at -80 °C
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for subsequent experiments. To purify mTORC2, cells
were lysed in lysis buffer (50 mM HEPES, pH 7.4,
150 mM NaCl, 2 % CHAPS, 1X Complete EDTA-free
protease inhibitor mixture (Roche Applied Science), and
1 mM Na3VO4). Cleared supernatant after centrifugation
(16,000 × g for 10 min) was mixed with anti-FLAG M2
magnetic beads (Sigma-Aldrich) for affinity purification.
The beads were collected, washed twice with wash buffer
containing ATP (50 mM HEPES, pH 7.4, 150 mM NaCl,
2 mM DTT, 2 mM ATP, 0.1 % CHAPS), and washed
three times with high salt wash buffer without ATP
(50 mM HEPES, pH 7.4, 300 mM NaCl, 2 mM DTT,
0.1 % CHAPS). The bound proteins were eluted from
magnetic beads using 3X FLAG peptide (Sigma-Aldrich)
in 50 mM HEPES, pH 7.4, 500 mM NaCl, 0.4 % CHAPS.
Eluted proteins were concentrated using Amicon Ultra
0.5-ml centrifugal filters NMWL 100 K (EMD Millipore,
Billerica, MA). For the experiment that required dissoci-
ation of mTOR from RICTOR, 1 % Triton X-100 was
substituted for 2 % CHAPS in the lysis buffer. When ne-
cessary, we included additional affinity purification to re-
move excess RICTOR by co-expressing AU1-mTOR and
using AU1-agarose beads. This yielded mTORC2 com-
plexes containing approximately equal amounts mTOR
and RICTOR proteins. This method is called two-step
purification. To perform this method, we first trans-
fected HEK293T stably expressing FLAG-RICTOR with
AU1-mTOR DNA for 48 h before cell collection. After
FLAG-beads purification, mTORC2 was further sub-
jected to another round of affinity purification using
AU1 beads and eluted with AU1 peptide. Silver staining
and Western blotting were performed to analyze the
purified mTORC2.
Mass spectrometry
In-gel trypsin digests and LC-MS/MS
The mTORC2 preparation was fractionated by SDS-
PAGE and gel slices from the 200–300 kDa MW region
were excised for MS analysis. Gel slices stained with
Gelcode Blue stain (Thermo Scientific) were washed
with a 1:1 mixture of 100 mM ammonium bicarbonate
(ABC) and acetonitrile. The gel was further destained
with 100 % acetonitrile and dried down by vacuum cen-
trifugation. Proteins in the gel slices were reduced with
10 mM DTT at 60 °C for 1 h followed by alkylation with
50 mM iodoacetamide at 45 °C for 45 min. Extensive
washing with 100 mM ammonium bicarbonate and
acetonitrile was performed prior to overnight trypsin di-
gestion with 15 ng sequencing grade trypsin (Promega).
The resulting tryptic peptides were extracted from the
gel slices with 30 μL of 50 % acetonitrile, 1 % TFA. Ex-
traction was repeated a total of three times and the ex-
tracted peptides were pooled prior to drying down by
vacuum centrifugation. Samples were reconstituted in
15 μL 1 % formic acid in water for MS analysis.
Tryptic peptides extracted from the gel bands were an-
alyzed by LC-MS/MS using an EASY-nLA 1000 HPLC
(Thermo Scientific) coupled to a Q-Exactive Orbitrap
mass spectrometer (Thermo Scientific) equipped with an
EASY-Spray nano-ESI source. 5 μL of each tryptic digest
sample were injected onto a 75 μm X 15 cm, 3 μ, 100 Å
PepMap C18 reversed-phase analytical LC column and
separated with a linear gradient of 100 % solvent A
(0.1 % formic acid in water) to 30 % solvent B (0.1 % for-
mic acid in acetonitrile) over 20 min at a constant flow
rate of 300 nL/min. Samples were analyzed using a Top
10 data-dependent acquisition method with 70,000 and
17,500 resolution at m/z 200 for MS1 and MS2 analysis
respectively. Raw data files were processed in Proteome
Discoverer (version 1.4, Thermo Scientific) using MAS-
COT (version 2.4.1; Matrix Science, London, UK) data-
base searching to identify proteins entrapped in the
200–300 kDa gel slices. Tryptic peptides with up to 2
missed cleavages were searched against the SwissProt
human database (2013) with the following settings: pre-
cursor and product ion mass tolerances of 10 ppm and
0.8 Da respectively, dynamic modification for oxidation
(M), static modification for carbamidomethyl (C).
Co-Immunoprecipitation
U87vIII cells were lysed with 2 % CHAPS lysis buffer
and centrifuged at 13200 RPM for 10 min. Cleared
supernatant was divided into groups to be incubated
with primary antibodies against mTOR, phospho-FLNA
(Ser2152), RICTOR and RAPTOR overnight at 4 °C. Con-
trol groups have no antibody. Then, Protein G superpara-
magnetic beads (Dynabeads; Life Technologies) were added
to each sample group and were rotated for 30-45 min at
4 °C. Immunoprecipitated and co-immunoprecipitated
proteins were detected using Western blotting analysis.
siRNA treatment
On-TARGET plus Smartpool Human RICTOR siRNA
was purchased from Thermo (Cat# 016984-00). U87vIII
cells were transfected using Lipofectamine RNAi max
(Life Technologies) and RICTOR siRNA or siGENOME-
non-targeting #1 (D-001206-13-05) for 24 h before
changing the media. All samples were collected 48 h
after siRNA treatment. Western blotting was performed
to show effects of RICTOR knockdown on FLNA phos-
phorylation. For immunofluorescence experiment, siRNA
transfected cells were transferred to 4-well chamber
slides 24 h after siRNA treatment and incubated for an-
other 24 h. Cells were then fixed, treated with anti-
FLNA, anti-RICTOR, phalloidin, followed by secondary
antibodies, and were observed under the fluorescent
microscope.
Chantaravisoot et al. Molecular Cancer  (2015) 14:127 Page 12 of 14
In vitro kinase assay
Kinase activities of mTORC2 from U87vIII cells express-
ing FLAG-RICTOR were examined in various conditions
using affinity purified mTORC2 as described above.
Purified FLNA protein (C-terminal fragment amino acid
1730–2639; Creative Biomart) from E. coli and purified
AKT protein (full-length; EMD Millipore) were used as
substrates for the kinase assay. In each reaction, purified
mTORC2 and its substrate (FLNA or AKT) were incu-
bated in a buffer containing 20 mM Tris-HCl (pH 7.5),
10 mM MgCl2, 0.2 mM ATP for 25 min. Negative con-
trol reactions contain either no ATP or no mTORC2.
MnCl2 was added to the positive control reaction. PP242
at two concentrations, 1.25 μM and 5 μM, and 40 μM of
IPA3 were added to the reactions to observe mTOR kin-
ase inhibition. Phosphorylation of FLNA (Ser2152) and
AKT (Ser473) were detected by Western blot analysis.
Additional files
Additional file 1: Figure S1. A. PP242 inhibits mTORC2 while PAK1
and MEK inhibitors do not. Cells were treated with inhibitors (PP242,
U0126, or IPA3) for 24 h and levels of phosphorylated FLNA, AKT, ERK,
and CRKII were examined by Western blotting analysis. B. RICTOR and
mTOR can be detected in either purified mTORC2 (Complex) or whole
cell lysate (WCL) from U87vIII cells while PKCα was found only in WCL.
Additional file 2: Figure S2. A. The treatment of PP242 at high
concentration (5 μM) does not affect U87vIII cell density. Phase contrast
pictures were taken at 24 h after the treatment. B. Invaded U87vIII cells
from different conditions, stained by crystal violet, on the membranes of
modified Boyden chambers are shown. Pictures were taken after a 24-h
invasion assay. (Ctrl = DMSO, P2.5 = PP242 2.5 μM, P5.0 = PP242 5.0 μM,
R = rapamycin 100 nM, U = U0126 10.0 μM).
Additional file 3: Figure S3. mTOR colocalizes with FLNA.
Immunofluorescence staining of U87vIII cells grown in normal condition
shows localization of mTOR and FLNA (Exposure time: FLNA 180 ms;
mTOR 525 ms; DAPI 42 ms). Both proteins are found colocalized along
the cell membrane.
Additional file 4: Figure S4. Results obtained from HEK293T cells
A. Silver-stained mTORC2 components (high molecular weight) purified
from HEK293T cells stably expressing FLAG-RICTOR are shown. Four large
proteins are numbered and labeled. B. Immunoblots of purified proteins
from HEK293T cells showing main components of mTORC2 (mTOR, RICTOR,
SIN1) including phosphorylated and total FLNA. C. In vitro kinase assay of
mTORC2 purified from HEK293T cells with FLNA and AKT as substrates. Level
of phosphorylated FLNA (Ser2152) and phosphorylated AKT (Ser473) were
increased in the presence of mTORC2 and ATP. D. Western blot shows levels
of pFLNA (Ser2152) in HEK293T cells treated with different concentrations
(0.31-5.0 μM) of PP242.
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